http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017020998-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_47b5902f4efe17cf235400422e2404b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_91e932c28e3b09362679f3826cfe67ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0ca0841c52dc980c3f201762d410f79b
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y305-01023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-12
filingDate 2016-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c3ab91c9232dfef9fa9add2a2899104
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0c70ccfa66ff008a65e53d86ab53d33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd35ad6c1fe1827407513205447c8cff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87d3f2b91a436dc227e302912bdd0656
publicationDate 2017-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2017020998-A1
titleOfInvention Ceramide levels in the treatment and prevention of infections
abstract The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients.
priorityDate 2012-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398685
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393830
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393829
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24749
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395180
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394880
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11177
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406750
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395921
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280335
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23830
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5143
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412246
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45051774
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394213
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394438
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4640
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409153
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409152
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1104
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3120
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36294
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4763
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24186254

Total number of triples: 52.